GVAG
BCRX icon

Great Valley Advisor Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Great Valley Advisor Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,400
Closed -$125K – 844
2024
Q3 		$125K Hold
16,400
– – ﹤0.01% 814
2024
Q2 		$101K Sell
16,400
-1,000
-6% -$5.52K ﹤0.01% 762
2024
Q1 		$88.3K Buy
17,400
+1,100
+7% +$6.19K ﹤0.01% 732
2023
Q4 		$97.6K Hold
16,300
– – ﹤0.01% 689
2023
Q3 		$115K Buy
16,300
+4,200
+35% +$30.2K ﹤0.01% 649
2023
Q2 		$85.2K Buy
12,100
+1,800
+17% +$14.4K ﹤0.01% 686
2023
Q1 		$85.9K Buy
+10,300
New +$99.2K ﹤0.01% 679

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Great Valley Advisor Group's BCRX Position: Q4 2024 in Review

Great Valley Advisor Group sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 16,400 shares — an estimated $125K sold.

Great Valley Advisor Group first reported a position in BCRX in Q1 2023 and held it in 7 quarters. The position peaked at $125K in Q3 2024. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Great Valley Advisor Group reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Great Valley Advisor Group sold 16,400 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $125K.
  • Great Valley Advisor Group first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Great Valley Advisor Group's BioCryst Pharmaceuticals position peaked at $125K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Great Valley Advisor Group's 13F filing for Q4 2024, filed 24 Feb 2025.